AI Article Synopsis
- Menopausal osteoporosis is linked to the end of ovarian function and can be influenced by various risk factors; monthly ibandronate treatment is preferred by women for better satisfaction and adherence.
- In a study involving 168 women, significant decreases in biochemical markers of bone resorption (beta-crosslaps and osteocalcin) were observed three months after starting a 150 mg monthly ibandronate treatment, indicating a reduction in bone loss.
- The findings suggest that biochemical markers can rapidly assess the effectiveness of the ibandronate therapy, contributing to the management of postmenopausal osteoporosis.
Article Abstract
Unlabelled: INTRODUCTION. Menopausal osteoporosis is a disease of older age, and its development is related to the cessation of ovarian function together with a number of risk factors. Monthly dosing regimens are welcomed by women because of higher satisfaction and better adherence. This study was aimed at assessing the therapeutic effect of ibandronate given once a month to women with postmenopausal osteoporosis on the basis of biochemical bone markers.
Material And Methods: We examined 168 patients of 268 patients in AD-HERO study. RocheDiagnostics, Elecsys beta-CrossLaps and beta-N-MID-Osteocalcin were used to measure beta-crosslaps before the therapy and 3 months after the therapy had been introduced as well as osteocalcin, which was measured in 12 patients.
Results: The value of beta-crosslaps before treatment was 0.5264 +/- 0.2926, that being above the upper limit of normal values for women in generative period, indicating an average of slightly increased bone resorption. Betacross-laps decreased and reached normal values for women in generative period 0.2277 +/- 0.1863 three months after the introduction of monthly ibandronat at a dose of 150 mg orally. This difference was highly statistically significant (t = 13.648, p < or = 0.0001). In 18 patients osteocalcin was measured before and three months after the introduction of the therapy. Osteocalcin was 31.3056 +/- 14.8209 before the treatment, which is normal for women of childbearing period. Osteocalcin decreased to 22.1822 +/- 6.9943 after three months, which is also within the normal range for women in the childbearing period of life. This difference was statistically significant (t =2.951, p < or = 0.001).
Conclusion: Monthly ibandronat suppresses bone resorption three months after the introduction of therapy. Biochemical bone markers quickly confirm the effect of medication, and they can be used in the assessment of effects on bone mineral density and future fracture risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2298/mpns1210379k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the impact of magnesium-based nutritional education on lipid profiles in individuals with type 2 diabetes mellitus: a quasi-experimental study.
Diabetol Metab Syndr
January 2025
Department of Clinical Nutrition, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Background: The potential therapeutic role of magnesium (Mg) in type 2 diabetes mellitus (T2DM) remains insufficiently studied despite its known involvement in critical processes like lipid metabolism and insulin sensitivity. This study examines the impact of Mg-focused nutritional education on lipid profile parameters, total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in T2DM patients.
Methods: Thirty participants with T2DM were recruited for this within-subject experimental study.
Factors associated with the dental service utilization by enrollees on the Lagos State health insurance scheme, Nigeria.
BMC Health Serv Res
January 2025
Oral Health Initiative, Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria.
Background: Despite assumptions that insurance coverage would boost oral healthcare utilization in Nigeria, there is insufficient evidence supporting this claim. This study investigates the associations between residential location, awareness of the oral health insurance scheme, history of dental service utilization, and acceptance of oral health insurance among individuals benefiting from the Ilera Eko Scheme; a scheme that integrates preventive and curative oral health care into the state health insurance scheme.
Methods: A cross-sectional survey was conducted from July to November 2023 recruiting from a database of 1520 enrollees aged of 18 and 72-years-old who had been on the scheme for at least three months.
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia.
Exp Hematol Oncol
January 2025
Bone Marrow Transplantation Center of The First Affiliated Hospital Liangzhu Laboratory, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, Zhejiang, China.
Background: Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited.
Methods: This study aimed to evaluate the efficacy and safety of sequential CD19 and CD22 CAR-T cell therapy in adult patients with R/R B-ALL between November 2020 and November 2023 (ChiCTR2100053871). Key endpoints included the adverse event incidence, overall survival (OS), and leukemia-free survival (LFS).
Providing an e-cigarette starter kit for smoking cessation and reduction as adjunct to usual care to smokers with a mental health condition: findings from the ESCAPE feasibility study.
BMC Psychiatry
January 2025
Department of Behavioural Science and Health, University College London, London, 1-19 Torrington Place, WC1E 7HB, UK.
Background: Smoking rates in the UK have declined steadily over the past decades, masking considerable inequalities, as little change has been observed among people with a mental health condition. This trial sought to assess the feasibility and acceptability of supplying an electronic cigarette (e-cigarette) starter kit for smoking cessation as an adjunct to usual care for smoking cessation, to smokers with a mental health condition treated in the community, to inform a future effectiveness trial.
Methods: This randomised controlled feasibility trial, conducted March-December 2022, compared the intervention (e-cigarette starter kit with a corresponding information leaflet and demonstration with Very Brief Advice) with a 'usual care' control at 1-month follow-up.
Dichotomitin promotes osteoblast differentiation and improves osteoporosis by inhibiting oxidative stress.
J Orthop Surg Res
January 2025
Research Institute of Orthopedics, The Affiliated Jiangnan Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Objective: Osteoporosis is a systemic disease with high morbidity and significant adverse effects. Increasing evidence supports the close relationship between oxidative stress and osteoporosis, suggesting that treatment with antioxidants may be a viable approach. This study evaluated the antioxidant properties of dichotomitin (DH) and its potential protective effects against osteoporosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!